Summary:
New Delhi: Predicting the global clamour for coronavirus vaccines - even as early as six months ago, when several candidates were still in late-stage clinical trials - could not have been "rocket science", AIIMS chief Dr Randeep Guleria told NDTV Friday night, as the centre responded to Serum Institute CEO Adar Poonawalla`s admission about existing production facilities being "very stressed".
.
New Delhi: Predicting the global clamour for coronavirus vaccines - even as early as six months ago, when several candidates were still in late-stage clinical trials - could not have been "rocket science", AIIMS chief Dr Randeep Guleria told NDTV Friday night, as the centre responded to Serum Institute CEO Adar Poonawalla`s admission about existing production facilities being "very stressed".
Dr Guleria`s comment comes two days after Mr Poonawalla told NDTV that the Serum Institute - makers of the Covishield vaccine, which is one of two in use in India - needed ? 3,000 crore and three months to scale up production to meet demand from both Indian and foreign governments.
"(on manufacturing capacity)...
something the manufacturer has to do.
They were aware of the (need to) supply not only India but the rest of the world.
To say now they will start manufacturing...
demand was always going to be huge.